Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Co. focuses on targeting and modulating N-methyl-D-aspartate receptors, or NMDArs, which are vital to normal and effective function of the brain and nervous system. Co.'s product candidates include: NYX-2925, which is for the treatment of chronic pain; NYX-783, which is for the treatment of Post-Traumatic Stress Disorder; and NYX-458, which is for the treatment of cognitive impairment associated with Parkinson's disease or dementia with Lewy bodies. The APTX stock yearly return is shown above.
The yearly return on the APTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the APTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|